Alleviating mucositis: are we on track for a novel therapeutic?

Abstract

Oral and gastrointestinal mucositis has emerged as an important toxicity of cancer therapy. In addition to supportive care measures, agents for the prevention or treatment of mucositis in specific patient populations are described in the evidence-based clinical practice guidelines published by the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. However, there still remains an unmet clinical need for preventive and therapeutic agents in several patient populations. The successful development of such agents will rely on our improved understanding of the pathogenic mechanisms underlying mucositis. Studies are also underway on novel delivery mechanisms and risk prediction models that can facilitate the selective use of interventions for mucositis in a targeted and cost–effective manner. A large number of agents are at various stages in the clinical development pipeline. Enhanced management of this dose-limiting toxicity will allow the delivery of optimal cancer therapy and improve patient prognosis.

Keywords:

• cancer
• chemotherapy
• gastrointestinal
• mucositis
• oral
• radiation therapy

Financial & competing interests disclosure

RV Lalla serves as Chair of the Mucositis Study Group of MASCC/ISOO and as Chair of the Mucositis Guidelines Panel. He has received research funding from BioAlliance Pharma and has served as a consultant for Sucampo AG, iNova Pharmaceuticals, Fera Pharmaceuticals and Phillips Gilmore Oncology Communications. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.